Rising Costs Weigh on Vertex Q1 Earnings

Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.Key MetricsMetricQ1 2024Q1 2025Changevs. ExpectationsTotal revenue$2.69 billion$2.77 billion+3%MissedAdjusted earnings per share$4.76$4.06-15%MissedTrikafta/Kaftrio revenue$2.48 billion$2.54 billion+2%n/aOther revenue$207 million$225 million+9%n/aVertex Hits a Speed BumpVertex's first-quarter financial results didn't keep up with what investors have gotten used to seeing in recent quarters. Revenue in Q1 rose jus ...